GU CANCERS
22 hours ago
Nano-Particles Show Breakthrough Potential in Fighting Prostate Cancer
A preclinical study led by researchers at Weill Cornell Medicine and the Cornell Duffield…
Cancer
22 hours ago
AROUND THE CORNER:Top Developments in Genitourinary Cancer Therapeutics
Enfortumab Vedotin Plus Pembrolizumab Reshapes the Perioperative MIBC Paradigm Representative trial: KEYNOTE-B15/EV-304 — Phase 3…
Cancer
23 hours ago
Most Clinically Significant Kidney Cancer Presentations from ASCO 2026
Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary.…
Cancer
23 hours ago
The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026
Thomas E. Hutson, DO, PharmD, FACP EDITORIAL NOTE | Editor-in-Chief, Kidney Cancer Journal …
ASCO
23 hours ago
ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights
[ A Summary Report from Kidney Cancer Journal ] Chicago, Illinois | May 29 –…
Conferences
October 26, 2022
ESMO’22 Recommended Abstracts in RENAL CANCERS
Robert A. Figlin, MD, Editor-in- Chief of the Kidney Cancer Journal. These recommended abstracts from ESMO…
Cancer
October 26, 2022
Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading
OCTOBER 17, 2022 – 4 MINUTES READ The activity of four specific genes in…
Cancer
October 26, 2022
A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies
Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD2 1. Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute,…
Conferences
October 26, 2022
2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy
ESMO’22 Special Robert A. Figlin, MD, FACS Cedars Cinai Cancer Center, Los Angeles, CA Correspondence:…
Kidney Cancer
October 26, 2022
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors
Grayce N. Selig, MD1 Christopher J. Hoimes, DO,2 Joe Bible, PhD,3 Daniel J. George, MD,2 Michael R. Harrison, MD2…
